Cargando…
Prediction of chemo-response in serous ovarian cancer
BACKGROUND: Nearly one-third of serous ovarian cancer (OVCA) patients will not respond to initial treatment with surgery and chemotherapy and die within one year of diagnosis. If patients who are unlikely to respond to current standard therapy can be identified up front, enhanced tumor analyses and...
Autores principales: | Gonzalez Bosquet, Jesus, Newtson, Andreea M., Chung, Rebecca K., Thiel, Kristina W., Ginader, Timothy, Goodheart, Michael J., Leslie, Kimberly K., Smith, Brian J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070116/ https://www.ncbi.nlm.nih.gov/pubmed/27756408 http://dx.doi.org/10.1186/s12943-016-0548-9 |
Ejemplares similares
-
Creation and validation of models to predict response to primary treatment in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2021) -
Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer
por: McDonald, Megan E., et al.
Publicado: (2019) -
Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer
por: Newtson, Andreea, et al.
Publicado: (2021) -
Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022) -
p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers
por: Devor, Eric J., et al.
Publicado: (2017)